Cargando…

EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations

AIMS: To evaluate congenital anomaly (CA)‐medication exposure associations produced by the new EUROmediCAT signal detection system and determine which require further investigation. METHODS: Data from 15 EUROCAT registries (1995–2011) with medication exposures at the chemical substance (5th level of...

Descripción completa

Detalles Bibliográficos
Autores principales: Given, Joanne E., Loane, Maria, Luteijn, Johannes M., Morris, Joan K., de Jong van den Berg, Lolkje T.W., Garne, Ester, Addor, Marie‐Claude, Barisic, Ingeborg, de Walle, Hermien, Gatt, Miriam, Klungsoyr, Kari, Khoshnood, Babak, Latos‐Bielenska, Anna, Nelen, Vera, Neville, Amanda J., O'Mahony, Mary, Pierini, Anna, Tucker, David, Wiesel, Awi, Dolk, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137835/
https://www.ncbi.nlm.nih.gov/pubmed/27028286
http://dx.doi.org/10.1111/bcp.12947
_version_ 1782471964458221568
author Given, Joanne E.
Loane, Maria
Luteijn, Johannes M.
Morris, Joan K.
de Jong van den Berg, Lolkje T.W.
Garne, Ester
Addor, Marie‐Claude
Barisic, Ingeborg
de Walle, Hermien
Gatt, Miriam
Klungsoyr, Kari
Khoshnood, Babak
Latos‐Bielenska, Anna
Nelen, Vera
Neville, Amanda J.
O'Mahony, Mary
Pierini, Anna
Tucker, David
Wiesel, Awi
Dolk, Helen
author_facet Given, Joanne E.
Loane, Maria
Luteijn, Johannes M.
Morris, Joan K.
de Jong van den Berg, Lolkje T.W.
Garne, Ester
Addor, Marie‐Claude
Barisic, Ingeborg
de Walle, Hermien
Gatt, Miriam
Klungsoyr, Kari
Khoshnood, Babak
Latos‐Bielenska, Anna
Nelen, Vera
Neville, Amanda J.
O'Mahony, Mary
Pierini, Anna
Tucker, David
Wiesel, Awi
Dolk, Helen
author_sort Given, Joanne E.
collection PubMed
description AIMS: To evaluate congenital anomaly (CA)‐medication exposure associations produced by the new EUROmediCAT signal detection system and determine which require further investigation. METHODS: Data from 15 EUROCAT registries (1995–2011) with medication exposures at the chemical substance (5th level of Anatomic Therapeutic Chemical classification) and chemical subgroup (4th level) were analysed using a 50% false detection rate. After excluding antiepileptics, antidiabetics, antiasthmatics and SSRIs/psycholeptics already under investigation, 27 associations were evaluated. If evidence for a signal persisted after data validation, a literature review was conducted for prior evidence of human teratogenicity. RESULTS: Thirteen out of 27 CA‐medication exposure signals, based on 389 exposed cases, passed data validation. There was some prior evidence in the literature to support six signals (gastroschisis and levonorgestrel/ethinylestradiol (OR 4.10, 95% CI 1.70–8.53; congenital heart disease/pulmonary valve stenosis and nucleoside/tide reverse transcriptase inhibitors (OR 5.01, 95% CI 1.99–14.20/OR 28.20, 95% CI 4.63–122.24); complete absence of a limb and pregnen (4) derivatives (OR 6.60, 95% CI 1.70–22.93); hypospadias and pregnadien derivatives (OR 1.40, 95% CI 1.10–1.76); hypospadias and synthetic ovulation stimulants (OR 1.89, 95% CI 1.28–2.70). Antipropulsives produced a signal for syndactyly while the literature revealed a signal for hypospadias. There was no prior evidence to support the remaining six signals involving the ordinary salt combinations, propulsives, bulk‐forming laxatives, hydrazinophthalazine derivatives, gonadotropin releasing hormone analogues and selective serotonin agonists. CONCLUSION: Signals which strengthened prior evidence should be prioritized for further investigation, and independent evidence sought to confirm the remaining signals. Some chance associations are expected and confounding by indication is possible.
format Online
Article
Text
id pubmed-5137835
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-51378352016-12-15 EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations Given, Joanne E. Loane, Maria Luteijn, Johannes M. Morris, Joan K. de Jong van den Berg, Lolkje T.W. Garne, Ester Addor, Marie‐Claude Barisic, Ingeborg de Walle, Hermien Gatt, Miriam Klungsoyr, Kari Khoshnood, Babak Latos‐Bielenska, Anna Nelen, Vera Neville, Amanda J. O'Mahony, Mary Pierini, Anna Tucker, David Wiesel, Awi Dolk, Helen Br J Clin Pharmacol Pharmacoepidemiology AIMS: To evaluate congenital anomaly (CA)‐medication exposure associations produced by the new EUROmediCAT signal detection system and determine which require further investigation. METHODS: Data from 15 EUROCAT registries (1995–2011) with medication exposures at the chemical substance (5th level of Anatomic Therapeutic Chemical classification) and chemical subgroup (4th level) were analysed using a 50% false detection rate. After excluding antiepileptics, antidiabetics, antiasthmatics and SSRIs/psycholeptics already under investigation, 27 associations were evaluated. If evidence for a signal persisted after data validation, a literature review was conducted for prior evidence of human teratogenicity. RESULTS: Thirteen out of 27 CA‐medication exposure signals, based on 389 exposed cases, passed data validation. There was some prior evidence in the literature to support six signals (gastroschisis and levonorgestrel/ethinylestradiol (OR 4.10, 95% CI 1.70–8.53; congenital heart disease/pulmonary valve stenosis and nucleoside/tide reverse transcriptase inhibitors (OR 5.01, 95% CI 1.99–14.20/OR 28.20, 95% CI 4.63–122.24); complete absence of a limb and pregnen (4) derivatives (OR 6.60, 95% CI 1.70–22.93); hypospadias and pregnadien derivatives (OR 1.40, 95% CI 1.10–1.76); hypospadias and synthetic ovulation stimulants (OR 1.89, 95% CI 1.28–2.70). Antipropulsives produced a signal for syndactyly while the literature revealed a signal for hypospadias. There was no prior evidence to support the remaining six signals involving the ordinary salt combinations, propulsives, bulk‐forming laxatives, hydrazinophthalazine derivatives, gonadotropin releasing hormone analogues and selective serotonin agonists. CONCLUSION: Signals which strengthened prior evidence should be prioritized for further investigation, and independent evidence sought to confirm the remaining signals. Some chance associations are expected and confounding by indication is possible. John Wiley and Sons Inc. 2016-07-07 2016-10 /pmc/articles/PMC5137835/ /pubmed/27028286 http://dx.doi.org/10.1111/bcp.12947 Text en © 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Pharmacoepidemiology
Given, Joanne E.
Loane, Maria
Luteijn, Johannes M.
Morris, Joan K.
de Jong van den Berg, Lolkje T.W.
Garne, Ester
Addor, Marie‐Claude
Barisic, Ingeborg
de Walle, Hermien
Gatt, Miriam
Klungsoyr, Kari
Khoshnood, Babak
Latos‐Bielenska, Anna
Nelen, Vera
Neville, Amanda J.
O'Mahony, Mary
Pierini, Anna
Tucker, David
Wiesel, Awi
Dolk, Helen
EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations
title EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations
title_full EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations
title_fullStr EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations
title_full_unstemmed EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations
title_short EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations
title_sort euromedicat signal detection: an evaluation of selected congenital anomaly‐medication associations
topic Pharmacoepidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137835/
https://www.ncbi.nlm.nih.gov/pubmed/27028286
http://dx.doi.org/10.1111/bcp.12947
work_keys_str_mv AT givenjoannee euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT loanemaria euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT luteijnjohannesm euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT morrisjoank euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT dejongvandenberglolkjetw euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT garneester euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT addormarieclaude euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT barisicingeborg euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT dewallehermien euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT gattmiriam euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT klungsoyrkari euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT khoshnoodbabak euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT latosbielenskaanna euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT nelenvera euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT nevilleamandaj euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT omahonymary euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT pierinianna euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT tuckerdavid euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT wieselawi euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations
AT dolkhelen euromedicatsignaldetectionanevaluationofselectedcongenitalanomalymedicationassociations